QUICK TAKE: MSD PACT FIRES UP DIVI’S

The Divi’s Laboratories stock was up over 8 per cent in trade on Monday after it became the authorised active pharmaceutical ingredient maker for global pharma major MSD’S Covid-19 drug, Molnupiravir. The oral drug could reduce the risk of hospitalisation or death by 50 per cent, says MSD

“On a more cautious note, earnings growth for next year in Asia is going to be more moderate at only 10% or so”

ANDREW GILLAN

Head of Asia ex-japan equities, Janus Henderson Investors